2016-08-08T13:39:53-05:00 2015-12-31 521855942 Tate and Tryon 2021 L Street NW Suite 400 Washington DC 20036 990 2015-01-01 521906152 PARENTERAL DRUG ASSOCIATION INC PARE 3016565900 4350 EAST WEST HIGHWAY BETHESDA MD 20814 JENNIFER BELL CFO 3016565900 2016-08-08 1 Elizabeth Heller P00397829 2022932200 2015 2016-12-15 16:53:06Z RICHARD JOHNSON 4350 EAST WEST HIGHWAY BETHESDA MD 20814 12106050 0 X WWW.PDA.ORG X 1994 DC TO BE THE FOREMOST GLOBAL PROVIDER OF SCIENCE, TECHNOLOGY AND REGULATORY INFORMATION AND EDUCATION FOR THE PHARMACEUTICAL AND BIOPHARMACEUTICAL COMMUNITY. 17 16 49 2331 239101 -762 215791 209967 11294624 10376107 271073 282768 998309 1006897 12779797 11875739 51624 0 0 0 5177083 5572435 0 0 0 6733527 6471494 11962234 12043929 817563 -168190 10591407 10346004 3912012 4269683 6679395 6076321 X TO DEVELOP SCIENTIFICALLY SOUND, PRACTICAL TECHNICAL INFORMATION AND RESOURCES TO ADVANCE SCIENCE AND REGULATION FOR THE PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY THROUGH THE EXPERTISE OF OUR GLOBAL MEMBERSHIP. 0 0 Programs & Meetings-Educate members and non-members by teaching developments in manufacturing and quality control for primary sterile product development. Training & Research Institute (TRI)Educational courses - technical training for scientists in the pharmaceutical areas of manufacturing, development and quality control.Training- Train members and non-members to basic manufacturing techniques centered around GMP guidelines. Membership & Chapter Services-Provide the latest guidelines focusing on technology information on manufacturing, technical reports, and quality control. Publication Sales- Provide the latest Science, Technology and Regulatory InformationSales, Exhibit & Sponsorship, Advertising- Provide the latest Science, Technology and Regulatory Information 0 1 0 1 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 1 93 0 1 49 1 1 1 0 0 0 1 1 0 X 17 16 0 0 0 0 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 0 0 MD X JENNIFER BELL 3016565900 4350 EAST WEST HIGHWAY BETHESDA MD 20814 HAROLD BASEMAN CHAIR 1.50 1.00 X X 21000 0 0 MARTIN VANTRIESTE CHAIR-ELECT 1.50 1.00 X X 0 0 0 REBECCA DEVINE PHD TREASURER 1.50 1.00 X X 0 0 0 MICHAEL SADOWSKI SECRETARY 1.50 1.00 X X 1200 0 0 ANDERS VINTHER PHD IMMEDIATE PAST CHAIR 1.50 1.00 X X 0 0 0 Masahiro Akimoto DIRECTOR 1.50 1.00 X 0 0 0 Deborah Autor DIRECTOR 1.50 1.00 X 0 0 0 JOYCE BLOOMFIELD DIRECTOR 1.50 1.00 X 0 0 0 URSULA BUSSE DIRECTOR 1.50 1.00 X 0 0 0 JETTE CHRISTENSEN DIRECTOR 1.50 1.00 X 0 0 0 VERONIQUE DAVOUST DIRECTOR 1.50 1.00 X 0 0 0 IAN ELVINS DIRECTOR 1.50 1.00 X 0 0 0 GABRIELE GORI DIRECTOR 1.50 1.00 X 0 0 0 Emma Ramnarine DIRECTOR 1.50 1.00 X 0 0 0 STEPHAN ROENNINGER DIRECTOR 1.50 1.00 X 0 0 0 Lisa Skeens PhD DIRECTOR 1.50 1.00 X 0 0 0 GLENN WRIGHT DIRECTOR 1.50 1.00 X 0 0 0 RICHARD JOHNSON PRESIDENT 37.50 1.00 X 397707 0 66223 CRAIG ELLIOTT CFO 37.50 0.00 X 297349 0 50938 RICHARD LEVY SR VP, SCI & REG AFFAIRS 37.50 0.00 X 310244 0 69187 WANDA O NEAL SR VP, PROG/REGIS 37.50 0.00 X 254593 0 54818 ROBERT L DANA SR VP, TRAINING & RESEARCH 37.50 0.00 X 200038 0 34786 DAVID HALL VP, SALES 37.50 0.00 X 203481 0 32031 Debbie A Goldstein Sr. Director of Marketing 37.50 0.00 X 139866 0 13324 Walter Morris DIR OF PUBLICATIONS 37.50 0.00 X 116315 0 25139 Denyse Baker Sr. Regulatory Advisor 37.50 0.00 X 111377 0 9714 Feng Chen DIRECTOR OF IT 37.50 0.00 X 111815 0 29743 Jennifer Bell Controller 37.50 0.00 X 108915 0 22936 2273900 0 408839 12 0 1 0 DHI PUBLISHING LLC 7727 E Valley View Road Scottsdale AZ 85250 BOOK SALES 189822 CLEANROOM COMPLIANCE INC 2136 JERRY LANE LODI CA 95242 INSTRUCTOR 115500 2 20000 189967 189967 209967 MEETINGS, EXHIBITS & CONFERENCES 541900 5210955 5210955 EDUCATION 541900 2773387 2773387 MEMBERSHIP DUES 900099 2391765 2391765 10376107 282768 282768 54681 54681 28521 0 28521 28521 28521 839515 230311 609204 609204 ADVERTISING 541800 239101 239101 Other Revenue 900099 75390 75390 314491 11875739 10985311 239101 441360 2025285 2551728 170987 528481 295954 21761 38910 727740 520035 1331108 795856 544104 1972331 352974 54593 MISCELLANEOUS EXPENSE 111984 foreign exchange adjust 98 12043929 1582200 1590601 7162781 6967945 55918 50351 83108 83306 350075 348787 4306690 3085210 1329147 1221480 28178 83534 10591407 10346004 1387803 1371392 2333426 2791019 190783 107272 3912012 4269683 X 6679395 6076321 6679395 6076321 10591407 10346004 -168190 -434884 0 X X 0 1 X 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 1227640 1129476 98164 1355562 590085 765477 1723488 1365649 357839 1221480 DEFERRED RENT 96496 DUE TO CHAPTERS 10776 107272 X 11693466 -434884 22300 -412584 12106050 -230311 -230311 11875739 12296540 22300 230311 252611 12043929 0 12043929 Part X, Line 2: THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY INCOME TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE ANY UNCERTAIN INCOME TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. THE ORGANIZATION'S INCOME TAX RETURNS ARE GENERALLY SUBJECT TO EXAMINATION BY TAXING AUTHORITIES FOR THREE YEARS AFTER THEY ARE FILED. Part XI, Line 4b - Other Adjustments: cogs to revenue part viii -230,311. Part XII, Line 2d - Other Adjustments: cogs to revenue part viii 230,311. South Asia 0 0 PROGRAM SERVICES TRAINING 67457 0 0 0 0 0 0 67457 0 67457 0 0 0 0 0 0 X 1 1 X X X X 0 0 0 RICHARD JOHNSON PRESIDENT 319942 0 77175 0 590 0 40050 0 36695 0 474452 0 0 0 CRAIG ELLIOTT CFO 249177 0 47730 0 442 0 45400 0 9317 0 352066 0 0 0 RICHARD LEVY SR VP, SCI & REG AFFAIRS 259151 0 50599 0 494 0 45530 0 28225 0 383999 0 0 0 WANDA O NEAL SR VP, PROG/REGIS 213334 0 40884 0 375 0 44291 0 18454 0 317338 0 0 0 ROBERT L DANA SR VP, TRAINING & RESEARCH 199796 0 0 0 242 0 32190 0 5429 0 237657 0 0 0 DAVID HALL VP, SALES 203237 0 0 0 244 0 14526 0 19566 0 237573 0 0 0 Debbie A Goldstein Sr. Director of Marketing 131546 0 8125 0 195 0 4232 0 11743 0 155841 0 0 0 Part I, Line 1a PDA pays 90% of the cost for use of a health club (Gym) for all of its employees. FORM 990 PART VII & SCHEDULE J: PDA UTILIZES THE SERVICES OF A PROFESSIONAL EMPLOYER ORGANIZATION (PEO), WHICH ACTS AS CO-EMPLOYER FOR PDA EMPLOYEES REPORTED IN THIS FORM 990. X LAB SUPPLIES 15 189967 FAIR MARKET VALUE 0 0 0 Form 990, Part VI, Section A, line 1 THE EXECUTIVE COMMITTEE CONSISTS OF THE ELECTED OFFICERS, IMMEDIATE PAST CHAIRMAN, AND PRESIDENT. IT SHALL ACT ON BEHALF OF THE BOARD OF DIRECTORS IN THE OPERATION OF THE ASSOCIATION AND SHALL HAVE SUCH AUTHORITY AS MAY BE ESTABLISHED FROM TIME TO TIME BY THE BOARD OF DIRECTORS. Form 990, Part VI, Section A, line 6 The association has individual members. The association does not have any stock holders. Form 990, Part VI, Section A, line 7a PDA'S GLOBAL MEMBERSHIP IS ELIGIBLE TO VOTE TO ELECT PDA'S BOARD OF DIRECTORS. THE PROCESS IS AS FOLLOWS: A NOMINATING COMMITTEE, CONSISTING OF THE CHAIRMAN, CHAIRMAN-ELECT, AND IMMEDIATE PAST CHAIRMAN, SUBMITS TO THE BOARD OF DIRECTORS A SLATE WITH (2) NOMINATED CANDIDATES FOR EACH OFFICER POSITION AND (2) NOMINATED CANDIDATES FOR EACH ELECTED DIRECTOR POSITION. THE BOARD OF DIRECTORS, THEN VOTES TO SELECT 1 CANDIDATE FOR EACH OPEN OFFICER POSITION AND 2 FOR DIRECTORS TO SEND TO THE FULL MEMBERSHIP FOR VOTING. AN ELECTRONIC BALLOT CONTAINING THE NAMES OF ALL CANDIDATES FOR ELECTION, WITH PROVISION FOR A "WRITE-IN" CANDIDATE FOR EACH POSITION TO BE FILLED, IS THEN PROVIDED TO EACH ASSOCIATION MEMBER ENTITLED TO VOTE. Form 990, Part VI, Section A, line 7b bylaws amendment process: Each proposed amendment of PDA's Bylaws, approved by vote of at least twelve (12) Directors, shall be submitted with a ballot to all PDA members entitled to vote. A proposed Bylaws amendment shall become effective upon receiving a two-thirds (2/3) "yes" vote of the member ballots received. Form 990, Part VI, Section B, line 11 THE FORM 990 IS REVIEWED BY THE PRESIDENT AND EXECUTIVE COMMITTEE MEMBERS. THE FORM 990, IN PDF FILE FORMAT, IS THEN PROVIDED TO THE FULL GOVERNING BODY (BOARD OF DIRECTORS) PRIOR TO FILING. Form 990, Part VI, Section B, line 12c FROM PDA'S CONFLICT OF INTEREST POLICY: 1. Duty to Disclose In connection with any actual or possible conflict of interest, an interested person must disclose the existence of the financial interest and be given the opportunity to disclose all material facts to the directors and members of committees with governing board delegated powers considering the proposed transaction or arrangement. 2. Determining Whether a Conflict of Interest Exists After disclosure of the financial interest and all material facts, and after any discussion with the interested person, he/she shall leave the governing board or committee meeting while the determination of a conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. 3. Procedures for Addressing the Conflict of Interest a. An interested person may make a presentation at the governing board or committee meeting, but after the presentation, he/she shall leave the meeting during the discussion of, and the vote on, the transaction or arrangement involving the possible conflict of interest. b. The chairperson of the governing board or committee shall, if appropriate, appoint a disinterested person or committee to investigate alternatives to the proposed transaction or arrangement. c. After exercising due diligence, the governing board or committee shall determine whether PDA can obtain with reasonable efforts a more advantageous transaction or arrangement from a person or entity that would not give rise to a conflict of interest. d. If a more advantageous transaction or arrangement is not reasonably possible under circumstances not producing a conflict of interest, the governing board or committee shall determine by a majority vote of the disinterested directors whether the transaction or arrangement is in PDA's best interest, for its own benefit, and whether it is fair and reasonable. In conformity with the above determination it shall make its decision as to whether to enter into the transaction or arrangement. 4. Violations of the Conflicts of Interest Policy a. If the governing board or committee has reasonable cause to believe a member has failed to disclose actual or possible conflicts of interest, it shall inform the member of the basis for such belief and afford the member an opportunity to explain the alleged failure to disclose. b. If, after hearing the member's response and after making further investigation as warranted by the circumstances, the governing board or committee determines the member has failed to disclose an actual or possible conflict of interest, it shall take appropriate disciplinary and corrective action. Form 990, Part VI, Section C, line 19 ASSOCIATION BYLAWS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MAINTAINED AND AVAILABLE TO THE ASSOCIATION'S GOVERNING BODIES AND MEMBERS. FORM 990, PART XII, LINE 2C THE AUDIT REVIEW PROCESS HAS REMAINED UNCHANGED FROM THE PRIOR YEAR. FOUNDATION FOR PHARMACEUTICAL EDUCATION TRAINING AND RESEARCH 4350 EAST WEST HWY STE 200 BETHESDA MD 20814 522075244 SUPPORT EDUCATION, TRAINING AND RESEARCH IN THE PHARMACEUTICAL SCIENCES DC 501(c)(3) Line 11b, II 1 pda europe gemeinnutzige gmbh Am Borsigturm 60 BERLIN GM 13507 SHARES PDA MISSION AS STATED ON PAGE 1 OF THIS FORM 990 GM NONPROFIT GERMAN com 1 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 pdA EUROPE GEMEINNUTZIGE GMBH E 26856 Net due to/from activity